Crispr Therapeutics AG vs Goodyear Tire & Rubber Co — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Goodyear Tire & Rubber Co trades at $4.68 (market cap $1.37B). The key difference: Crispr Therapeutics AG is far larger — about 3.6× Goodyear Tire & Rubber Co's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Goodyear Tire & Rubber Co for 57 Days on average.
| CRSP | GT | |
|---|---|---|
Market Cap | $4.88B | $1.37B |
Volume | 2,861,747 | 9,470,773 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $10.54 |
52-Week Low | $44.34 | $4.66 |
Typical Hold Time | 77 Days | 57 Days |
Enterprise Value | $3.30B | $8.72B |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
The Goodyear Tire & Rubber Company (GT) trades at $4.75, down 1.28% with a bearish technical outlook. The stock shows attractive valuation metrics with P/E of 4.69 and P/B of 0.48, but faces fundamental challenges including negative net income margin of -14.37% and ROE of -63.93%. Recent earnings showed mixed results with Q2 2026 beating expectations despite a loss, while the company executes a restructuring strategy focusing on premium EV tires.
GT presents a high-risk opportunity with significant upside potential given the $8.00 consensus price target, but investors face substantial execution risks amid ongoing restructuring, declining revenues, and persistent losses. The bearish technicals and mixed analyst sentiment (34.62% buy rating) suggest cautious optimism dependent on successful turnaround execution and margin improvement.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →